Advertisement
Canada markets closed
  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CAD/USD

    0.7322
    +0.0021 (+0.28%)
     
  • CRUDE OIL

    83.30
    +1.40 (+1.71%)
     
  • Bitcoin CAD

    90,756.50
    -80.58 (-0.09%)
     
  • CMC Crypto 200

    1,431.01
    +16.25 (+1.15%)
     
  • GOLD FUTURES

    2,336.80
    -9.60 (-0.41%)
     
  • RUSSELL 2000

    2,002.60
    +35.13 (+1.79%)
     
  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     
  • NASDAQ

    15,696.64
    +245.33 (+1.59%)
     
  • VOLATILITY

    15.84
    -1.10 (-6.49%)
     
  • FTSE

    8,044.81
    +20.94 (+0.26%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6837
    -0.0013 (-0.19%)
     

Teva Pharmaceutical: Still Focused on New Product Launches

Teva Pharmaceutical: Still Focused on New Product Launches

Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.